biostudies-literatureCao ZCentral South University9013283https://www.ebi.ac.uk/biostudies/studies/S-EPMC7661137biostudies-literatureUnknown2020<h4>Objective</h4>Most guidelines recommend the use of nonsteroidal anti-inflammatory drugs (NSAIDs), duloxetine, and tramadol for the nonoperative treatment of osteoarthritis (OA), but the use of them is limited by the tolerability and safety concerns. Lutikizumab is a novel anti-IL-1<i>α</i>/<i>β</i> dual variable domain immunoglobulin that can simultaneously bind and inhibit IL-1<i>α</i> and IL-1<i>β</i> to relieve the pain and dysfunction symptoms. We conducted this network meta-analysis to comprehensively compare the clinical efficacy and safety of lutikizumab with other drugs recommended by guidelines.<h4>Methods</h4>We conducted a Bayesian network and conventional meta-analyses to compare the efficacy and safety of lutikizumab with other traditional drugs. All eligible randomized clBioMed research internationalIs Lutikizumab, an Anti-Interleukin-1&lt;i&gt;α&lt;/i&gt;/&lt;i&gt;β&lt;/i&gt; Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis.PMC7661137GCX20190879YLi YCao ZLong ZHu XDou PWu RWang WWu TAili DJie SZhou JfalseIs Lutikizumab, an Anti-Interleukin-1&lt;i&gt;α&lt;/i&gt;/&lt;i&gt;β&lt;/i&gt; Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis.<h4>Objective</h4>Most guidelines recommend the use of nonsteroidal anti-inflammatory drugs (NSAIDs), duloxetine, and tramadol for the nonoperative treatment of osteoarthritis (OA), but the use of them is limited by the tolerability and safety concerns. Lutikizumab is a novel anti-IL-1<i>α</i>/<i>β</i> dual variable domain immunoglobulin that can simultaneously bind and inhibit IL-1<i>α</i> and IL-1<i>β</i> to relieve the pain and dysfunction symptoms. We conducted this network meta-analysis to comprehensively compare the clinical efficacy and safety of lutikizumab with other drugs recommended by guidelines.<h4>Methods</h4>We conducted a Bayesian network and conventional meta-analyses to compare the efficacy and safety of lutikizumab with other traditional drugs. All eligible randomized cl2020-01-01T00:00:00Z20202026-07-09T10:43:59.176Z2025-05-29T19:36:58.506ZS-EPMC76611373320472610.1155/2020/9013283